<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335736</url>
  </required_header>
  <id_info>
    <org_study_id>AA2015</org_study_id>
    <nct_id>NCT02335736</nct_id>
  </id_info>
  <brief_title>Antagonist Protocol in IVF</brief_title>
  <official_title>Can Antagonist Protocol be the Protocol of Choice in in Vitro Fertilization Patients?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woman's Health University Hospital, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Woman's Health University Hospital, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The antagonist protocol in a novel method of stimulation in the in vitro fertilization (IVF)
      patients. It has been tried in poor responders, polycystic ovary (PCO) patients and normal
      females undergoing IVF. Can it be used with the same efficacy in all patients?
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of oocytes collected and fertilized</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poor responders</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polycystic ovarian disease</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant(Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotropins releasing hormone antagonist</intervention_name>
    <arm_group_label>Normal</arm_group_label>
    <arm_group_label>Poor responders</arm_group_label>
    <arm_group_label>Polycystic ovarian disease</arm_group_label>
    <other_name>Cetrotide, Serono, Geneva, Switzerland</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age: 20- 44 years

          -  Poor responder females according to Bologna criteria

          -  Polycystic ovarian disease females according to Rotterdam criteria

          -  Females with infertility causes other than poor responders, or PCO; male factor or
             tubal block

        Exclusion Criteria:

          -  refusal to get enrolled in the study

          -  cases of infertility due to severe male factor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina M Dakhly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dina M Dakhly, MD</last_name>
    <phone>01003498919</phone>
    <phone_ext>002</phone_ext>
    <email>dinadakhly@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>mohamed abdalla, MD</last_name>
    <phone>01001721206</phone>
    <phone_ext>002</phone_ext>
    <email>mohamedhassan100@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kasr el aini hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina M Dakhly, MD</last_name>
      <phone>01003498919</phone>
      <phone_ext>002</phone_ext>
      <email>Dinadakhly@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dina M Dakhly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2015</study_first_submitted>
  <study_first_submitted_qc>January 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2015</study_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woman's Health University Hospital, Egypt</investigator_affiliation>
    <investigator_full_name>Dina Mohamed Refaat Dakhly</investigator_full_name>
    <investigator_title>lecturer of obstetrics and gynecology</investigator_title>
  </responsible_party>
  <keyword>infertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Cetrorelix</mesh_term>
    <mesh_term>Menotropins</mesh_term>
    <mesh_term>Hormone Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

